Following Compass' Lead
Executive Summary
Corporate venture investment programs like Guidant's Compass walk a thin line between traditional business development and traditional venture capital investing. Compass' goal is to help Guidant find new technology early that could eventually help one of Guidant's core business groups but still earn a return on investment in the event the technology ultimately proves of no value to the corporation.
You may also be interested in...
Corporate Venture Capital's Complex Agenda
Several forces--rapid technological obsolescence, the impact of information technology on health care, merger integrations, and the need for double digit revenue growth--have caused increasing numbers of large pharmaceutical and medical device companies to create new corporate venture capital groups. But compared to traditional VC firms, whose only goal is to make money for limited partners, corporate VCs have a heavy agenda. They must choose portfolio companies while balancing often-competing goals of strategic benefit and financial return.
FDA’s Califf Calls For Return To Large, Simple Trials Without The ‘Useless Stuff’ That Slows Development
US FDA Commissioner Califf praises both Project Pragmatica and the ‘very powerful’ partnership between OCE Director Rick Pazdur and National Cancer Institute Director Monica Bertagnolli.
California Prop 65 Complaints Against OTC Generics? Ranitidine Could Be First And Last Target
Marketers of copies of national brand OTCs are required under FDA regulations to use the same labeling as the brand, a rule that in effect has limited complaints in California state court alleging Prop 65 violations with nonprescription drug labeling to targeting branded product marketers.